Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Part 1 Inclusion Criteria:~A volunteer subject must meet all of the following criteria:~* 18 to 65 years old.~* Available for clinical follow-up through Week 48.~* Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.~* Must be willing to be taken home at enrollment visit and allow home visits if participant does not keep appointments~* Must complete an Assessment of Understanding successfully.~* Able to read (English or Luganda) and willing to complete the informed consent process.~* Willing to donate blood for sample storage to be used for future research.~* In good general health without clinically significant medical history.~* Physical examination and laboratory results without clinically significant findings and a body mass index (BMI) ≤ 40 within the 56 days prior to enrollment.~Laboratory Inclusion Criteria within 56 days prior to enrollment:~* Hemoglobin ≥ 11.0 g/dL for women; ≥12.5 g/dL for men.~* White blood cells (WBC) = 2,500-12,000 cells/mm3.~* WBC differential either within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval.~* Total lymphocyte count ≥ 800 cells/mm3.~* Platelets = 125,000 - 400,000/mm3.~* Alanine aminotransferase (ALT) ≤ 1.25 x upper limit of normal (ULN).~* Serum creatinine ≤ 1 x ULN.~* Partial thromboplastin time (PTT) within institutional normal range.~* Prothrombin time (PT) within institutional normal range.~* HIV-uninfected as evidenced by a negative FDA-approved HIV diagnostic test.~Female-Specific Inclusion Criteria:~* Negative β-HCG (human chorionic gonadotropin) pregnancy test on day of enrollment.~* Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 24 weeks after study vaccination if presumed to be of reproductive potential.~Part 1 Exclusion Criteria:~Volunteer has received any of the following substances:~* Investigational Ebola or Marburg vaccine (other than the Ebola DNA vaccine delivered in RV 247) in a prior clinical trial or prior receipt of a cAd3 adenoviral vectored investigational vaccine.~* Chronic use of immunomodulators and systemic glucocorticoids in daily doses of glucocorticoid equivalence \> 20 mg of prednisolone, for periods exceeding 10 days. Non-steroidal anti-inflammatory drugs \[NSAIDS\] are permitted.~* Participants that have used less than the stated glucocorticoid dose may still be excluded at the Investigator's discretion.~* Blood products within 112 days prior to enrollment.~* Investigational research agents within 28 days prior to enrollment.~* Live attenuated vaccines within 28 days prior to enrollment.~* Subunit or killed vaccines within 14 days prior to enrollment.~* Current anti-tuberculosis prophylaxis or therapy.~Female-Specific Exclusion Criteria:~* Woman who is breast-feeding or planning to become pregnant during the first 24 weeks after study vaccine administration.~Volunteer has a history of any of the following clinically significant conditions:~* Serious adverse reactions to vaccines such as anaphylaxis, urticaria (hives), respiratory difficulty, angioedema, or abdominal pain.~* Clinically significant autoimmune disease or immunodeficiency.~* Asthma that is not well controlled.~* Diabetes mellitus (type I or II), with the exception of gestational diabetes.~* Thyroid disease that is not well controlled.~* A history of hereditary angioedema (HAE), acquired angioedema (AAE), or idiopathic forms of angioedema.~* Idiopathic urticaria within the last 1 year.~* Hypertension that is not well controlled.~* Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.~* Malignancy that is active or history of a malignancy that is likely to recur during the period of the study.~* Seizure in the past 3 years or treatment for seizure disorder in the past 3 years.~* Asplenia or functional asplenia.~* Psychiatric condition that precludes compliance with the protocol; past or present psychoses; or within five years prior to enrollment, history of a suicide plan or attempt.~* Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.~Part 2 Inclusion Criteria:~* Received the Part 1 study injection and is willing to participate in Part 2.~* Satisfactory completion of the Assessment of Understanding~* Subject is assessed by the Site Principal Investigator or designee as in good general health without clinically significant medical history that precludes participation.~Female-Specific Inclusion Criteria:~* Negative β-HCG pregnancy test on day of enrollment if presumed to be of reproductive potential.~* Agrees to use an effective means of birth control from at least 21 days prior to enrollment through 24 weeks after study vaccination if presumed to be of reproductive potential.~Part 2 Exclusion Criteria:~* Type 1 hypersensitivity to aminoglycosides antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group 1a: cAd3-EBOZ at 1x10(10) PU (Type: EXPERIMENTAL): Part 1: cAd3-EBOZ at 1x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
- Group 1b: cAd3-EBOZ at 1x10(11) PU (Type: EXPERIMENTAL): Part 1: cAd3-EBOZ at 1x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
- Group 1c: cAd3-EBO at 2x10(10) PU (Type: EXPERIMENTAL): Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
- Group 1d: cAd3-EBO at 2x10(11) PU (Type: EXPERIMENTAL): Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
- Group 2a:cAd3-EBO at 2x10(10) PU (Type: EXPERIMENTAL): Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
- Group 2b: cAd3-EBO at 2x10(11) PU (Type: EXPERIMENTAL): Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete